Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：29

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[1] Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study
Hyvakka, Anniina
Kaariainen, Okko-Sakari
Utriainen, Tapio
Loyttyniemi, Eliisa
Mattila, Kalle
Reinikainen, Petri
Sormunen, Jorma
Jaaskelainen, Minna
Auvinen, Paivi
Minn, Heikki
Sundvall, Maria
[J]. CANCER MEDICINE, 2023, 12 (04): : 4064 - 4076
[2] Efficacy of radium-223 dichloride in castration-resistant metastatic prostate cancer
Sobrevilla Calvo, Pedro de Jesus
[J]. GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 26 - 27
[3] Real-World Utilization And Outcomes Of Radium-223 In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
Li, R.
Dandapani, S. V.
Amini, A.
Pal, S. K.
Dorff, T. B.
Lyou, Y.
Vapiwala, N.
Wong, J. Y. C.
Glaser, S. M.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E885 - E886
[4] Radium-223 in metastatic castration resistant prostate cancer
Vuong, Winston
Sartor, Oliver
Pal, Sumanta K.
[J]. ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 348 - 353
[5] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
Lapierre, M.
Fraelic, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
[6] Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective
Shore, Neal D.
[J]. UROLOGY, 2015, 85 (04) : 717 - 724
[7] A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Kim, Stephanie, I
Szeto, Andy H.
Morgan, Katherine P.
Brower, Blaine
Dunn, Mary W.
Khandani, Amir H.
Godley, Paul A.
Rose, Tracy L.
Basch, Ethan M.
Milowsky, Matthew, I
Whang, Young E.
Crona, Daniel J.
[J]. PLOS ONE, 2021, 16 (06):
[8] Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
Anido-Herranz, Urbano
Fernandez-Calvo, Ovidio
Ruiz-Banobre, Juan
Martinez-Breijo, Sara
Fernandez-Nunez, Natalia
Nogareda-Seoane, Zulema
Garrido-Pumar, Miguel
Casas-Nebra, Javier
Muniz-Garcia, Gloria
Portela-Pereira, Paula
Gomez-Caamano, Antonio
Perez-Fentes, Daniel Adolfo
Santome-Couto, Lucia
Lazaro, Martin
Molina-Diaz, Aurea
Medina-Colmenero, Ana
Vazquez-Estevez, Sergio
[J]. FRONTIERS IN ONCOLOGY, 2024, 14
[9] Radium-223 Dichloride in Peritoneal Dialysate Following Treatment of Metastatic Castration-resistant Prostate Cancer
Saganich, Christopher
Zgaljardic, Michael
[J]. HEALTH PHYSICS, 2022, 122 (03): : 433 - 439
[10] RADIUM-223: TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
James, D.
Hillery, R.
Freeman, L.
Kumari, A.
Kearney, N.
[J]. INTERNAL MEDICINE JOURNAL, 2016, 46 : 30 - 31

← 1 2 3 4 5 →